Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Pulmicort Respules 1 mg /2 ml Nebuliser Suspension
Medicines register · Ireland

Pulmicort Respules 1 mg /2 ml Nebuliser Suspension

Authorisation PA1019/017/002 · AstraZeneca AB

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 21 Nov 2026
Licence holder
AstraZeneca AB (all products →)
Active substance
Budesonide
Clinical trials
15 clinical trials →
Dosage form
Nebuliser suspension
Route of administration
Inhalation use
ATC codes
R03BA, R03BA02
First authorised
27/02/2001
Prescription status
Product subject to prescription which may be renewed (B)
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Budesonide: supply and approvals

37 authorised products on the HPRA list contain Budesonide. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 20 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 20 Nov 2026)
Germany (BfArM)
3 supply notices, e.g. Cyclocaps Budesonid 200 µg (1 Aug 2025 to 31 Dec 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 25 years (since 27 February 2001). The HPRA list marks it as marketed in Ireland.

Other medicines with Budesonide in Ireland

35 other products on the HPRA list contain Budesonide, from 10 licence holders; 20 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
AirBuFo Forspiro 160 microgram/4.5 microgram/dose inhalation powder, pre-dispensedRowex Limited,National authorisation (PA)Marketed
AirBuFo Forspiro 320 microgram/9 microgram/dose inhalation powder, pre-dispensedRowex Limited,National authorisation (PA)Marketed
Budenofalk 2mg/dose rectal foamDr. Falk Pharma GmbHNational authorisation (PA)Marketed
Budenofalk 3 mg gastro-resistant capsulesDr. Falk Pharma GmbHNational authorisation (PA)Marketed
Budenofalk® 9mg gastro-resistant granulesDr. Falk Pharma GmbHNational authorisation (PA)Marketed
Budesonide Azure 0.5 mg/2 ml Nebuliser SuspensionAzure Pharmaceuticals Ltd.National authorisation (PA)Marketed
Budesonide Azure 1 mg/2 ml Nebuliser SuspensionAzure Pharmaceuticals Ltd.National authorisation (PA)Marketed
Budesonide Teva Pharma 0.5 mg/2 ml Nebuliser SuspensionTeva Pharma B.V.National authorisation (PA)Marketed
Budesonide Teva Pharma 1 mg/2 ml Nebuliser SuspensionTeva Pharma B.V.National authorisation (PA)Marketed
Bufomix Easyhaler 160 micrograms/4.5 micrograms/inhalation, inhalation powderOrion CorporationNational authorisation (PA)Marketed
Bufomix Easyhaler 320 micrograms/9 micrograms/inhalation, inhalation powderOrion CorporationNational authorisation (PA)Marketed
Bufomix Easyhaler 80 micrograms/4.5 micrograms/inhalation, inhalation powderOrion CorporationNational authorisation (PA)Marketed

All 36 products with Budesonide →

Other substances in ATC group R03BA

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 5 other active substances share the group R03BA with this product:

Beclometasone dipropionate (16) · Fluticasone propionate (12) · Ciclesonide (3) · Mometasone furoate (2) · Beclometasone dipropionate anhydrous (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

AstraZeneca AB holds 69 products on the HPRA list, with 43 different active substances; 9 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.